Emma Walmsley Buys 8 Shares of GlaxoSmithKline plc (GSK) Stock

GlaxoSmithKline plc (LON:GSK) insider Emma Walmsley bought 8 shares of GlaxoSmithKline stock in a transaction dated Thursday, January 10th. The stock was purchased at an average price of GBX 1,524 ($19.91) per share, for a total transaction of £121.92 ($159.31).

Emma Walmsley also recently made the following trade(s):

  • On Tuesday, December 11th, Emma Walmsley bought 8 shares of GlaxoSmithKline stock. The stock was purchased at an average price of GBX 1,494 ($19.52) per share, for a total transaction of £119.52 ($156.17).

Shares of LON GSK opened at GBX 1,507.80 ($19.70) on Monday. GlaxoSmithKline plc has a 12-month low of GBX 1,235.20 ($16.14) and a 12-month high of GBX 1,724.50 ($22.53).

The business also recently declared a dividend, which was paid on Thursday, January 10th. Investors of record on Thursday, November 15th were given a dividend of GBX 19 ($0.25) per share. The ex-dividend date was Thursday, November 15th. This represents a yield of 1.26%.

GSK has been the topic of several recent analyst reports. Barclays restated an “overweight” rating on shares of GlaxoSmithKline in a research note on Monday, September 24th. Jefferies Financial Group restated a “buy” rating and issued a GBX 1,580 ($20.65) target price on shares of GlaxoSmithKline in a research note on Friday, October 12th. UBS Group restated a “buy” rating and issued a GBX 1,700 ($22.21) target price on shares of GlaxoSmithKline in a research note on Thursday, September 27th. Deutsche Bank set a GBX 1,520 ($19.86) target price on shares of GlaxoSmithKline and gave the company a “neutral” rating in a research note on Thursday, December 20th. Finally, Goldman Sachs Group set a GBX 1,900 ($24.83) target price on shares of GlaxoSmithKline and gave the company a “buy” rating in a research note on Tuesday, December 25th. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and eight have assigned a buy rating to the company’s stock. GlaxoSmithKline has a consensus rating of “Hold” and a consensus target price of GBX 1,530.34 ($20.00).

ILLEGAL ACTIVITY NOTICE: This report was first published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this report on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The original version of this report can be read at https://www.thelincolnianonline.com/2019/01/14/emma-walmsley-buys-8-shares-of-glaxosmithkline-plc-gsk-stock.html.

About GlaxoSmithKline

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Read More: What is a blue-chip stock?

Insider Buying and Selling by Quarter for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply